Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

@article{Gottlieb2014SafetyOI,
  title={Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.},
  author={Alice Bendix Gottlieb and Robert E. Kalb and Richard B. Langley and Gerald G. Krueger and Elke M G J De jong and Lynn Guenther and Kavitha G Goyal and Steven Fakharzadeh and Marc Chevrier and Stephen Calabro and Wayne Langholff and Alan Menter},
  journal={Journal of drugs in dermatology : JDD},
  year={2014},
  volume={13 12},
  pages={1441-8}
}
BACKGROUND Long-term data are essential to assess the safety of biologic agents for the treatment of psoriasis. OBJECTIVE To evaluate the incidence of adverse events of interest (AEIs), including all-cause mortality, major adverse cardiovascular events (MACE), malignancy (excluding nonmelanoma skin cancer), and serious infections (SI), in patients treated for psoriasis in clinical practice settings. METHODS PSOLAR is a large, ongoing, observational study of patients receiving, or eligible… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…